Hurren KM - Search Results

1

Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.

Hurren KM, Dunham MW. Hurren KM, et al. Expert Opin Pharmacother. 2018 Jul;19(10):1087-1095. doi: 10.1080/14656566.2018.1494727. Epub 2018 Jul 11. Expert Opin Pharmacother. 2018. PMID: 29958007 Review.

2

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Pinelli NR, Hurren KM. Pinelli NR, et al. Among authors: hurren km. Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5. Ann Pharmacother. 2011. PMID: 21730278 Review.

3

Naltrexone/bupropion: an investigational combination for weight loss and maintenance.

Makowski CT, Gwinn KM, Hurren KM. Makowski CT, et al. Among authors: hurren km. Obes Facts. 2011;4(6):489-94. doi: 10.1159/000335352. Epub 2011 Dec 15. Obes Facts. 2011. PMID: 22249001 Free PMC article. Review.

4

Drug-drug interactions with glucagon-like peptide-1 receptor agonists.

Hurren KM, Pinelli NR. Hurren KM, et al. Ann Pharmacother. 2012 May;46(5):710-7. doi: 10.1345/aph.1Q583. Epub 2012 Apr 17. Ann Pharmacother. 2012. PMID: 22510669 Review.

5

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review.

Berlie H, Hurren KM, Pinelli NR. Berlie H, et al. Among authors: hurren km. Diabetes Metab Syndr Obes. 2012;5:165-74. doi: 10.2147/DMSO.S27528. Epub 2012 Jul 3. Diabetes Metab Syndr Obes. 2012. PMID: 22826635 Free PMC article.

6

Evaluation of lorcaserin for the treatment of obesity.

Berlie HD, Hurren KM. Berlie HD, et al. Among authors: hurren km. Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1053-9. doi: 10.1517/17425255.2013.798643. Epub 2013 Jun 26. Expert Opin Drug Metab Toxicol. 2013. PMID: 23802690 Review.

7

Ranolazine and Its Effects on Hemoglobin A1C.

Greiner L, Hurren K, Brenner M. Greiner L, et al. Ann Pharmacother. 2016 May;50(5):410-5. doi: 10.1177/1060028016631757. Epub 2016 Feb 25. Ann Pharmacother. 2016. PMID: 26917816 Review.

8

Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.

Hurren KM, O'Neill JL. Hurren KM, et al. Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1521-1526. doi: 10.1080/17425255.2016.1245722. Epub 2016 Oct 18. Expert Opin Drug Metab Toxicol. 2016. PMID: 27710135 Review.

9

Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.

Hurren KM, Dunham MW. Hurren KM, et al. Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):891-896. doi: 10.1080/17425255.2017.1344214. Epub 2017 Jul 11. Expert Opin Drug Metab Toxicol. 2017. PMID: 28636828 Review.

10

Are thiazolidinediones a preferred drug treatment for type 2 diabetes?

Hurren KM, Dunham MW. Hurren KM, et al. Expert Opin Pharmacother. 2021 Feb;22(2):131-133. doi: 10.1080/14656566.2020.1853100. Epub 2020 Dec 7. Expert Opin Pharmacother. 2021. PMID: 33280446 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results